Drug Profile
Tigecycline - Pfizer
Alternative Names: GAR 936; TBG-Mino; Tigilcycline; Tygacil; WAY 156936; WAY-GAR-936Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antibacterials; Glycylcyclines; Small molecules
- Mechanism of Action Mitochondrial protein inhibitors; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Community-acquired pneumonia; Intra-abdominal infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Discontinued Diabetic foot ulcer; Mycobacterial infections; Nosocomial pneumonia; Ventilator associated pneumonia